All In Biotech

Drug Trial Radar · NCT06109441

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 4, 2023

Primary completion

Mar 5, 2026

Study completion Mar 2028

Sponsor

Lead sponsor
AltruBio Inc.Industry
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase and a LTE (Long Term Extension)

Conditions

  • Ulcerative Colitis

Interventions

  • ALTB-268Biological

    ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy - change in mMSTime frame: week 12

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • San Diego Gastroenterology

    San Diego, California

  • Rocky Mountain Gastroenterology

    Littleton, Colorado

  • Gastro Health Research

    Miami, Florida

  • Digestive and Liver Center of Florida, LLC

    Orlando, Florida

  • Alliance Clinical Research of Tampa, LLC.

    Tampa, Florida

  • Gastro Health Partners Southern Indiana

    New Albany, Indiana

  • Gastro Health Partners Louisville

    Louisville, Kentucky

  • Louisiana Research Center, LLC.

    Shreveport, Louisiana

  • Gastroenterology Associates of North Mississippi

    Oxford, Mississippi

  • New York Presbyterian Hospital - Weill Cornell Medical Colllege

    New York, New York

  • Gastroenterology Group of Rochester

    Rochester, New York

  • Digestive Disease Medicine of Central New York

    Utica, New York

  • Dayton Gastroenterology, LLC

    Beavercreek, Ohio

  • Gastro Health Ohio

    Liberty Township, Ohio

  • Frontier Clinical Research, LLC

    Uniontown, Pennsylvania

  • Gastroenterology Associates, P.A.

    Greenville, South Carolina

  • DHAT / GI Aliance

    Garland, Texas

  • Caprock Gastro Reasearch

    Lubbock, Texas

  • GI Alliance

    Mansfield, Texas

  • Southern Star Research Institute LLC

    San Antonio, Texas

  • Tyler Research Institute

    Tyler, Texas

  • GI Alliance

    Webster, Texas

  • Wisconsin Center for Advanced Research

    Milwaukee, Wisconsin

  • Wellness Clinical Research, LLC

    Vega Baja, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.